Fast As A Whip, Pfizer Files Personalized Lung Cancer Drug Crizotinib
This article was originally published in The Pink Sheet Daily
One of three Pfizer cancer drugs to be filed in 2011, crizotinib may help to turn the tide on pipeline setbacks. Axitinib and bosutinib filings are still to come.
You may also be interested in...
Diagnostic Industry Trends Hinge On Gene-Based Tests
In 2011, sequencing was once again the big story in diagnostics. But unlike 2010 when the big news was the successful IPOs of next-generation sequencing companies Pacific Biosciences and Complete Genomics, the tone in 2011 was more nuanced.
Pfizer’s Second Market For Targeted Lung Cancer Drug Xalkori Is Korea
After winning regulatory approval Dec. 29, Pfizer launches Xalkori in Korea, leveraging a clinical program that has included a significant percentage of Korean patients.